Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Carmustine (BCNU)

3

I.x Pleuroparenchymal fibroelastosis (PPFE)

2
Last update : 01/05/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Bendamustine
1
Fotemustine
1
Lomustine (CCNU)
3
Nitrosoureas (suffixes '-NU', '-mustine')
4

Publications

Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.
The European respiratory journal 2014 Aug;44;523-7 2014 Aug
Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?
The European respiratory journal 2014 Aug;44;289-96 2014 Aug
Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
Mayo Clinic proceedings 2003 May;78;630-4 2003 May
Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances.
Seminars in respiratory and critical care medicine 2003 Aug;24;445-54 2003 Aug
Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features.
Clinical radiology 1991 Nov;44;299-301 1991 Nov
Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
Chest 1977 Sep;72;372-3 1977 Sep

Powered by

  • ^
  • Contact
  • Cookies
  • About